Ravi Vij

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
    Rizwana Chohan
    Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia and Bone Marrow Transplantation, St Louis, MO 63110 1093, USA
    Br J Haematol 123:110-3. 2003
  2. doi request reprint An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    Ravi Vij
    Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Haematol 158:739-48. 2012
  3. doi request reprint An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Ravi Vij
    Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 119:5661-70. 2012
  4. ncbi request reprint Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
  5. ncbi request reprint Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
  6. ncbi request reprint Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage
    Aarti Oza
    Department of Internal Medicine, Division of Oncology, Barnes Jewish Hospital, Washington University School of Medicine, and Siteman Cancer Center, St Louis, Missouri 63110 1093, USA
    Transfusion 46:14-23. 2006
  7. ncbi request reprint A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007
  8. ncbi request reprint Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Christopher L Hallemeier
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 12:749-57. 2006
  9. ncbi request reprint Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
    Mark Girgis
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 105:3035-41. 2005
  10. pmc A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Todd A Fehniger
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA
    Blood 117:1828-33. 2011

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity
    Rizwana Chohan
    Washington University School of Medicine, Department of Medicine, Division of Oncology, Section of Leukaemia and Bone Marrow Transplantation, St Louis, MO 63110 1093, USA
    Br J Haematol 123:110-3. 2003
    ..GVHD and/or infection occurred in 54% and were the most common primary causes of death. We conclude that calcineurin inhibitor-induced neurotoxicity is frequently reversible but associated with a poor prognosis...
  2. doi request reprint An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
    Ravi Vij
    Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Haematol 158:739-48. 2012
    ....
  3. doi request reprint An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Ravi Vij
    Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 119:5661-70. 2012
    ..1% overall (1 grade 3; no grade 4)-in these pretreated bortezomib-naive patients. The results of the present study support the use of carfilzomib in R/R MM patients. This trial is registered at www.clinicaltrials.gov as NCT00530816...
  4. ncbi request reprint Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
    ..This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population...
  5. ncbi request reprint Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
    ..No patient on LDSC GCV exhibited a decline in their ANC below 500/microl and none required growth factors. LDSC GCV is extremely well tolerated and cost-effective as PT for CMV viremia following allo-PBSC transplantation...
  6. ncbi request reprint Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage
    Aarti Oza
    Department of Internal Medicine, Division of Oncology, Barnes Jewish Hospital, Washington University School of Medicine, and Siteman Cancer Center, St Louis, Missouri 63110 1093, USA
    Transfusion 46:14-23. 2006
    ....
  7. ncbi request reprint A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007
    ..15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival...
  8. ncbi request reprint Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Christopher L Hallemeier
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 12:749-57. 2006
    ..In patients with MDS, this is an effective RIC regimen for allogeneic transplantation that can be used as an alternative to other RIC or conventional conditioning regimens...
  9. ncbi request reprint Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide
    Mark Girgis
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 105:3035-41. 2005
    ..This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM...
  10. pmc A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Todd A Fehniger
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA
    Blood 117:1828-33. 2011
    ..HD lenalidomide has evidence of clinical activity as initial therapy for older AML patients, and further study of lenalidomide in AML and MDS is warranted. This study is registered at www.clinicaltrials.gov as #NCT00546897...
  11. doi request reprint Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma
    Tanya M Wildes
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:840-6. 2008
    ..Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their association with outcomes...
  12. doi request reprint Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Mike G Martin
    Section of Leukemia and Bone Marrow Transplantation, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, USA
    Am J Hematol 84:733-7. 2009
    ..The patients who received G-CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc...
  13. ncbi request reprint Bortezomib inhibits osteoclast activity in patients with multiple myeloma
    Geoffrey L Uy
    Section of Bone Marrow Transplant and Leukemia, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Lymphoma Myeloma 7:587-9. 2007
    ..Although NF-kappaB inhibition is predicted to affect osteoclast function, preclinical and clinical studies have primarily reported an effect on osteoblasts...
  14. pmc A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
    Geoffrey L Uy
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
    Blood 119:3917-24. 2012
    ..We conclude that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis...
  15. pmc Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Jacob P Smeltzer
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 17:1646-52. 2011
    ..2 (confidence interval [CI] 1.1-9.0, P = .03). Pre-ASCT FDG-PET scans predict EFS in patients with relapsed cHL patients treated with modern salvage/ASCT therapy and warrant prospective evaluation...
  16. doi request reprint Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Iskra Pusic
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1045-56. 2008
    ..Patients who fail initial mobilization are more likely to fail remobilization. These findings suggest that there is a need for more effective first-line mobilization agents...
  17. ncbi request reprint Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study
    William Blum
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110 1093, USA
    Biol Blood Marrow Transplant 9:397-404. 2003
    ..Efficacy with TBI conditioning may be reduced compared with high-dose melphalan, but this should be explored in a future trial with a larger cohort of patients...
  18. doi request reprint An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
    Ravi Vij
    Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Am J Hematol 84:650-6. 2009
    ..Additional controlled clinical studies of denosumab in subjects with both relapsed and plateau-phase MM are warranted...
  19. ncbi request reprint Recent advances in allogeneic hematopoietic stem-cell transplantation
    Steven M Devine
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine
    J Lab Clin Med 141:7-32. 2003
  20. ncbi request reprint Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
    Amy L Hoerr
    School of Medicine, Siteman Cancer Center, Washington University, St Louis, MO, USA
    J Clin Oncol 22:4561-6. 2004
    ..To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL)...
  21. pmc Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
    Todd A Fehniger
    Department of Internal Medicine, Division of Oncology, Siteman Cancer Center, Washington University, St Louis, MO, USA
    Blood 113:1002-5. 2009
    ..The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897...
  22. doi request reprint Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Shivaprasad Manjappa
    Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
    Biol Blood Marrow Transplant 20:46-52. 2014
    ....
  23. doi request reprint A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
    Mike G Martin
    Washington University School of Medicine, Saint Louis, Missouri 63110, USA
    Am J Hematol 84:560-4. 2009
    ..This regimen appeared to offer a PR + CR rate and median DOR somewhat similar to what has been reported with the 7-day subcutaneous regimen; however, OS was shorter...
  24. pmc Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma
    Vishwanathan Hucthagowder
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
    Cancer Genet 205:474-8. 2012
    ....
  25. doi request reprint Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature
    Mike G Martin
    Section of Leukemia and Bone Marrow Transplantation, Division of Oncology, Washington University School of Medicine, Saint Louis, MO 63110, USA
    Clin Lymphoma Myeloma 9:320-3. 2009
    ..We also review the literature on arterial thromboembolic events in patients taking thalidomide. Care should be taken in future trials to document arterial events with both thalidomide and lenalidomide...
  26. pmc Influence of body mass index on survival in veterans with multiple myeloma
    Tracey S Beason
    Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    Oncologist 18:1074-9. 2013
    ..We also evaluated the association between weight loss in the year prior to diagnosis and survival...
  27. pmc Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma
    Julie O'Neal
    Department of Internal Medicine, Division of Oncology, Washington University, Siteman Cancer Center, St Louis, MO, USA
    Exp Hematol 37:234-44. 2009
    ..We sought to identify tumor-suppressor genes on chromosome 13 using a novel array comparative genomic hybridization (aCGH) strategy...
  28. pmc Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress
    Liang Chu
    Division of Oncology, Washington University School of Medicine, St Louis, MO, USA
    J Clin Invest 122:2793-806. 2012
    ....
  29. doi request reprint Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004
    Giridharan Ramsingh
    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer 115:5734-9. 2009
    ..Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL...
  30. doi request reprint Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia
    George Ansstas
    Washington University of St Louis, St Louis, MO 63110, USA
    Leuk Lymphoma 53:1273-81. 2012
    ..It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making...
  31. doi request reprint Molecular pathology of myeloproliferative neoplasms
    Jeffery M Klco
    Dept of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Pathol 133:602-15. 2010
    ..This review summarizes the salient characteristics of the MPNs, with emphasis on recent developments in the molecular pathophysiology and therapeutic monitoring of these disorders...
  32. doi request reprint Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  33. doi request reprint Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
    Drew J Winston
    University of California, Los Angeles Medical Center, Los Angeles, CA 90095, USA
    Blood 111:5403-10. 2008
    ..Maribavir had no adverse effect on neutrophil or platelet counts. These results show that maribavir can reduce the incidence of CMV infection and, unlike ganciclovir, does not cause myelosuppression...
  34. ncbi request reprint The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma
    Geoffrey L Uy
    Haematologica 91:1581-2. 2006
    ..No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment...
  35. ncbi request reprint Cancer- and chemotherapy-induced anemia
    George M Rodgers
    Huntsman Cancer Institute, University of Utah, Utah, USA
    J Natl Compr Canc Netw 6:536-64. 2008